

DOCUMENTS CONSIDERED BY MICHAEL MAYERSOHN, PH.D.

DOC. NO.	DOCUMENT DESCRIPTION
1	U.S. Patent No. 7,932,268 (Rader)
2	U.S. Patent No. 8,618,135 (Rader)
3	“Bayer/PPD Implitapide Development Follows Zetia Model As Statin Add-On,” <i>The Pink Sheet</i> , 66(7):17 (February 16, 2004)
4	Stein Presentation re Microsomal Triglyceride Transfer Protein (MTP) Inhibitor (implitapide) program (2004)
5	Chandler et al., “CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans,” <i>Journal of Lipid Research</i> , 44:1887-1901 (2003)
6	Chang et al., “Microsomal triglyceride transfer protein (MTP) inhibitors: Discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms,” <i>Current Opinion in Drug Discovery & Development</i> , 5(4):562-570 (2002)
7	Shiomi & Ito, “MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion,” <i>European Journal of Pharmacology</i> , 431:127-131 (2001)
8	Wetterau et al., “An MTP Inhibitor that Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits,” <i>Science</i> , 282:751-754 (1998)
9	Rowland & Tozer, <i>Clinical Pharmacokinetics: Concepts and Applications</i> , 57, 98 (1995)
10	Certified U.S. Provisional Patent Application No. 60/550,915
11	“Half-Year Pharma Operating Highlights,” <i>The Pink Sheet</i> , 62(31):19-20 (July 31, 2000)

Petition for *Inter Partes* Review of USPN 7,932,268

DOC. NO.	DOCUMENT DESCRIPTION
12	Mayersohn, "Principles and Applications of Pharmacokinetics," <i>Medical Toxicology</i> , 282- 337 (2004)
13	Margaret A. McDowell et al., "Anthropometric Reference Data for Children and Adults: U.S. Population, 1999-2002," <i>CDC Advance Data from Vital & Health Stats.</i> , 361 (2005).